YouBest Biotechnology: Leading a New Era of Precision Diagnosis for Bloodstream Infections with Patented HNL Technology

In the field of bloodstream infection (BSI) diagnostics, time is life. Traditional detection methods are often time-consuming and lack specificity. These critical limitations are being addressed by the biomarker Human Neutrophil Lipocalin (HNL). In this emerging and innovative field, YouBest Biotechnology Co., Ltd. (Zhejiang) has built a strong “patent moat” around its HNL-based diagnostic technology through forward-looking strategy and core technological accumulation—demonstrating exceptional industry leadership.

Recognizing the clinical value of innovative diagnostic tools, YouBest has taken the lead in optimizing and implementing HNL detection technology. Its independently developed HNL immunofluorescence quantitative detection reagent has officially obtained the Chinese Medical Device Registration Certificate (Registration No. 20242401994)—filling a critical domestic gap.

This product enables quantitative detection of HNL levels in human blood, allowing rapid identification of bacterial bloodstream infections within 1–2 hours. It achieves a sensitivity of 92% and a specificity exceeding 85%, offering a fast and effective new diagnostic option. It provides critical diagnostic support during the golden window period for severe infections such as sepsis and septicemia.

Obtaining the registration certificate is only the beginning. The real competitive edge lies in deep control and legal protection of core technologies. YouBest has successfully obtained a highly valuable national invention patent:

• Patent Title: Use of HNL in the preparation of reagents for identifying bloodstream infections

• Patent Certificate No.: 7968169

• Patent No.: ZL 2024 1 1942805.8

🚀 Patent Significance:

• Core Protection: This patent secures the application of HNL as a biomarker in the development of diagnostic reagents for bloodstream infections.

• Strategic Value: It serves not only as an official recognition of YouBest’s technological leadership but also as a strategic tool to build market barriers and prevent imitation.

  
  

The patent authorization (Granted on May 30, 2025; Authorization No. CN 119375492B) provides robust legal support for YouBest’s priority position in the BSI precision diagnostics market.

🔍 Patent Highlights:

• Originality: The world’s first patent defining HNL’s clinical value in bloodstream infection diagnostics.

• Exclusivity: Comprehensive protection covering reagent design, detection methodology, and clinical indications.

• Long-Term Value: Patent rights extend through 2044, offering sustained market protection for nearly two decades.

From obtaining a single-marker registration certificate for market access, to securing an application patent that protects core innovation, and further to implementing a dual-focus strategy aligned with clinical needs—this fully reflects the company's:

• Profound technological foundation: A deep understanding of the clinical value of the HNL biomarker and strong capability in translating it into practical applications.

• Forward-looking patent strategy: Proactive development of an intellectual property system to safeguard innovation and ensure sustainable competitiveness.

• Keen clinical insight: Continuous optimization and upgrading of diagnostic solutions centered on unmet clinical needs.

• Comprehensive product pipeline: A well-structured portfolio ranging from single-marker to combined detection assays, designed to meet diverse diagnostic scenarios.